In conclusion, the therapeutic potential of GLP-1 receptor agonists, insulin analogs, metformin, and PPARγ agonists lies in their ability to target various pathophysiological mechanisms in AD, offering hope for more effective treatments. The gene discussed is PPARG; the disease is Alzheimer disease.